Payment overview · 2025
General Payments
$930.22
40 reported records · 12 companies
Healthcare provider profile · identity verified
Walter Thomas, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · CULVER CITY, CA · NPI 1154516789
Verified facts
What the public records show
CMS Open Payments records show Walter Thomas, PAC received $930.22 in general payments during 2025 across 40 reported records.
Amgen Inc. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $229.66 | 24.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.34 | 20.5% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.70 | 18.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.23 | 9.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.54 | 7.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.30 | 4.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.84 | 3.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $28.14 | 3.0% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $25.92 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.22 | 2.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.26 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.07 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $930.22 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $185.15 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $185.15 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $117.63 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.43 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.54 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.54 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.07 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.45 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.57 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.66 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $5.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 110 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
110 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 882 | 290 |
| Metformin Hcl | Metformin Hcl | 476 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 158 |
| Losartan Potassium | Losartan Potassium | 273 | 87 |
| Lisinopril | Lisinopril | 257 | 78 |
| Simvastatin | Simvastatin | 249 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 55 |
| Omeprazole | Omeprazole | 191 | 71 |
| Gabapentin | Gabapentin | 168 | 50 |
| Benazepril Hcl | Benazepril Hcl | 161 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 51 |
| Metformin Hcl Er | Metformin Hcl | 154 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 43 |
| Ibuprofen | Ibuprofen | 139 | 42 |
| Glipizide | Glipizide | 130 | 46 |
| Alendronate Sodium | Alendronate Sodium | 128 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 30 |
| Farxiga | Dapagliflozin Propanediol | 110 | 33 |
| Ozempic | Semaglutide | 109 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 25 |
| Jardiance | Empagliflozin | 103 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 28 |
| Naproxen | Naproxen | 89 | 27 |
| Furosemide | Furosemide | 87 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 18 |
| Januvia | Sitagliptin Phosphate | 84 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 27 |
| Trazodone Hcl | Trazodone Hcl | 79 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 24 |
| Donepezil Hcl | Donepezil Hcl | 77 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 76 | 31 |
| Tramadol Hcl | Tramadol Hcl | 74 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 71 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 69 | 20 |
| Carvedilol | Carvedilol | 67 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 17 |
| Sertraline Hcl | Sertraline Hcl | 64 | 15 |
| Atenolol | Atenolol | 63 | 20 |
| Meloxicam | Meloxicam | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 18 |
| Famotidine | Famotidine | 49 | 13 |
| Glimepiride | Glimepiride | 47 | 15 |
| Lovastatin | Lovastatin | 45 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 18 |
| Finasteride | Finasteride | 41 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 40 | 14 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 29 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Ibu | Ibuprofen | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 15 | suppressed |
| Prolia | Denosumab | 15 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | 11 |
| Invokana | Canagliflozin | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $930.22 · 40 records | Amgen Inc. | ABRYSVO, AIRSUPRA, APTIMA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, KRYSTEXXA, M-M-R II, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PENBRAYA, PREVNAR 20, REPATHA, Rybelsus, TEPEZZA, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, TRUMENBA, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error